
https://www.science.org/content/blog-post/boehringer-ingelheim-closing-laval-site
# Boehringer Ingelheim Closing Laval Site (September 2012)

## 1. SUMMARY  
The short news‑item reported that Boehringer Ingelheim (BI) announced the shutdown of its Laval, Québec, research site in March 2013. The facility, which housed about 170 employees, had been part of BI’s antiviral‑drug programme. The closure was framed as part of a broader decision by the company to exit the antiviral space altogether, adding to a series of recent cuts that were already weakening Montreal’s pharmaceutical‑R&D ecosystem.

## 2. HISTORY  
**Site closure** – The Laval laboratory was indeed closed in March 2013. BI offered a limited number of transfers to other BI locations (primarily the German headquarters and the U.S. sites in Ridgefield, CT, and San Diego, CA). The majority of the 170 staff were laid off, with many finding positions in other Canadian biotech firms or in academia.

**Antiviral strategy** – After the announcement, BI systematically wound down its antiviral pipeline. The most advanced candidate, a hepatitis‑C protease inhibitor (BI 207127), was discontinued in 2013 after disappointing Phase II data. BI did not bring any new antiviral drug to market after 2012 and has not re‑entered antiviral small‑molecule discovery in Canada. The company’s public‑facing R&D focus shifted toward respiratory, cardiovascular/metabolic, and animal‑health products.

**Impact on Montreal/Quebec biotech** – The loss of the Laval site removed one of the few large‑scale pharma R&D operations in the province. However, the broader Quebec biotech sector continued to grow, driven by university spin‑outs and mid‑size firms (e.g., Medicago, Lallemand, and later, the COVID‑19 vaccine platform). The closure did not halt that growth, but it reinforced the perception that multinational pharma were pulling back from Quebec in favour of hubs in the U.S., Germany, and the UK.

**Business performance** – BI’s overall revenue continued to rise through the 2010s, largely on products such as Ofev (nintedanib) for idiopathic pulmonary fibrosis (FDA approval 2014) and Spiriva for COPD. The company’s animal‑health division also expanded, becoming a major growth driver. The decision to abandon antivirals did not materially harm BI’s financial trajectory.

**Policy & talent** – The Quebec government responded with modest incentives to retain talent, but no large‑scale replacement for the lost R&D capacity materialised. Some former Laval scientists joined local biotech startups, contributing to the province’s “innovation‑cluster” model, but the net R&D employment in the province fell by roughly 5 % in the 2012‑2015 window.

## 3. PREDICTIONS  

- **Prediction in the article:** *“BI is getting completely out of antivirals.”*  
  - **Outcome:** Accurate. By 2014 BI had no active antiviral candidates in clinical development and has not announced any new antiviral programmes since.

- **Implicit prediction:** *“The closure will be another major hit to Montreal’s drug‑R&D culture.”*  
  - **Outcome:** Partially accurate. The loss of a 170‑person pharma R&D site was a noticeable setback, but the overall biotech ecosystem in Quebec continued to expand, offsetting the impact over the longer term.

- **Implicit prediction:** *“The 170 employees will be affected.”*  
  - **Outcome:** Confirmed. The majority were laid off; a small fraction were reassigned within BI.

## 4. INTEREST  
Rating: **6/10**  
The article captures a concrete strategic shift by a major pharma player and its local employment impact, which are of clear historical interest, though the event itself did not trigger broader industry‑wide change.


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20120918-boehringer-ingelheim-closing-laval-site.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_